Diabetes

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.

A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.

Investigators conducted a study to assess the impact of combined diet and exercise interventions in patients with type 2 diabetes.

Results of the SOUL clinical trial will be presented at a scientific meeting in 2025.

Pharmacist-led medication therapy management can help reduce costs associated with diabetes management.

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

Researchers compared the cardiovascular outcomes of patients hospitalized for heart failure that did or did not experience diabetic emergencies.

Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.

Without financial incentives, some senators expressed concerns that pharmaceutical research and development would stall.

Senators sought to uncover why prices of Novo Nordisk’s GLP-1 receptor agonist semaglutide are significantly higher in the US compared with countries in Europe.

Two phase 3 trials demonstrated that once-weekly insulin efsitora is as effective as daily insulin in lowering HbA1c in both type 1 (T1D) and type 2 diabetes (T2D).

Embecta’s new patch pump offers a larger insulin reservoir to better accommodate for the needs of patients with type 2 diabetes (T2D).

Catch up on important diabetes news from the month of August.

The device was previously cleared for use in children and adults with type 1 diabetes.

Addressing the external factors that can have an impact on patient health can make clinical interventions more effective when administered.

Recent research on diabetes has examined its bidirectional relationship with mental health, the significant increase in prevalence over the last decade, and how both diet and exercise can help prevent type 2 diabetes.

Increased incidence of typed 2 diabetes was associated with higher consumption of processed meat, unprocessed red meat, and poultry.

A detailed report of study findings will be published in a peer-reviewed journal and presented at ObesityWeek 2024.

Timothy Mackey, MAS, PhD, discusses a study that sought to determine the risk of sourcing semaglutide from online platforms.

A collaboration with Blue Cross and Blue Shield of North Carolina focused on commercial populations has improved care and lowered costs in the state.

Both the restructuring of direct and indirect remuneration fees and health care cyber attacks made an impact on the industry in the first half of 2024.

To scale up diabetes intervention programs, sustainable workflows, trainings, and payment models are key.

A study found that CT scans of visceral fat had the highest predictive performance of incident diabetes.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Catch up on important diabetes news from the month of July.

From 2021 to 2022, the prevalence of adults with diabetes who used cannabis increased by 33.7%.

Patients with childhood type 1 diabetes were more likely to develop substance use disorders, mood disorders, anxiety disorders, and behavioral syndromes.

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

Previously, data from head-to-head trials of tirzepatide and semaglutide were not available.